Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 The Friday Brief for April 24, 2026: INTERPHEX Recap and Major Acquisitions | Contract Pharma

What are you searching for?

Sign in
Friday Brief, Videos

The Friday Brief for April 24, 2026: INTERPHEX Recap and Major Acquisitions

A major industry trade show dominated most of the week, but that doesn't mean other developments weren't happening.

Author Image

By: Patrick Lavery

Content Marketing Editor

Welcome to this week’s edition of The Friday Brief, in which the big attractions are INTERPHEX and acquisitions. At INTERPHEX in New York, our team engaged with companies along all points of the pharma value chain. Among these are some great upcoming, exclusive conversations with Dawsongroup tcs and Ecolab. Our editorial staff is busy churning out all of its content; you can look for it in the coming days at contractpharma.com.

Anytime there’s a major show in the industry, “breaking” news tends to slow down. But we do have a few noteworthy stories to share with you this week. Alcami has agreed to acquire Tjoapack, expanding Alcami’s presence in Europe. UCB has proposed a $650 million acquisition of Neurona Therapeutics. Servier completed the tender offer to buy out all stock of Day One Biopharmaceuticals. And Asahi Kasei completed its acquisition of Aicuris.

In collaborations, Merck is betting up to $1 billion on a partnership with Google Cloud to enhance Merck’s AI solutions. Andelyn Biosciences and ENCell are establishing a strategic manufacturing bridge between the U.S. and the Asia Pacific region.

And a few companies are expanding their capacities. AbbVie is making a $1.4 billion investment on a 185-acre pharma manufacturing campus in North Carolina. Meanwhile, Evonik will expand its biotech capabilities in Slovakia.

Still plenty going on this week, but again, stay up to date at contractpharma.com for our wrap-up coverage from INTERPHEX. And we’ll see you next week.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics